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Abstract 
Background: There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for 
neovascular age-related macular degeneration (NVAMD).
Methods: A Value-Based Medicine, 12-year, combined-eye model, cost-utility analysis evaluated genetic testing of 
Category 3 AMD patients at age 65 for progression to NVAMD. The benefit of genetic testing was predicated upon the 
fact that early-treatment ranibizumab therapy (baseline vision 20/40–20/80) for NVAMD confers greater patient value 
than late-treatment (baseline vision ≤20/160). Published genetic data and MARINA Study ranibizumab therapy data 
were utilized in the analysis. Patient value (quality-of-life gain) and financial value (2012 US real dollar) outcomes were 
discounted at 3 % annually.
Results: Genetic testing-enabled, early-treatment ranibizumab therapy per patient conferred mean 20/40−1 vision, a 
0.845 QALY gain and 14.1 % quality-of-life gain over sham therapy. Late-treatment ranibizumab therapy conferred mean 
20/160+2 vision, a 0.250 QALY gain and 4.2 % quality-of-life gain over sham therapy. The gain from early-treatment over 
late-treatment was 0.595 QALY (10.0 % quality-of-life gain). The per-patient cost for genetic testing/closer monitoring 
was $2205 per screened person, $2.082 billion for the 944,000 estimated new Category 3 AMD patients annually. Genetic 
testing/monitoring costs per early-treatment patient totaled $66,180. Costs per early-treatment patient included: genetic 
testing costs: $66,180 + direct non-ophthalmic medical costs: −$40,914 + caregiver costs: −$172,443 + employment 
costs: −$14,098 = a net societal cost saving of $160,582 per early treatment patient. When genetic screening facilitated 
an incremental 12,965 (8.0 %) of the 161,754, new annual NVAMD patients aged ≥65 in the US to undergo early-treat-
ment ranibizumab therapy, each additional patient treated accrued an overall, net financial gain for society of $160,582. 
Genetic screening was cost-effective, using World Health Organization criteria, when it enabled an incremental 4.1 % 
(6634) of 161,754 annual NVAMD patients ≥65 years to receive early-treatment ranibizumab therapy.
Conclusions: Genetic screening-enabled, early-treatment ranibizumab therapy for NVAMD is cost-effective if it 
enables an incremental 4.1 % of the annual US cohort of new-onset NVAMD patients ≥65 to undergo early-treatment 
with ranibizumab.
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Background
Age-related macular degeneration (AMD) is the lead-
ing cause of blindness in the ≥60-year-old population in 
the US [1]. Eye Diseases Prevalence Research Group [2] 
data suggest advanced AMD (central geographic atrophy 
and/or neovascular AMD) affected 1.87 million people 
in 2012 [3]. Among advanced AMD patients, 70  % had 
neovascular AMD (NVAMD) in one or both eyes [2]. 
Approximately 171,350 patients developed NVAMD 
annually [2, 3]. Among US citizens reaching age 65 annu-
ally, 944,400 have Category 3 drusen [2, 3].
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Several models predict the conversion of atrophic 
AMD to NVAMD, each using the Age Related Eye 
Diseases Study (AREDS) classification of AMD [4–
8]. The more complex model in AREDS Report No. 
17 [6], evaluated the eyes of 3212 participants, uti-
lizing drusen severity and pigmentary abnormalities 
at baseline. The authors proposed a 9-step severity 
scale that combined a 6-step drusen area scale with 
a 5-step pigmentary abnormality scale. The 5-year 
risk of progression to advanced AMD varied from 
<1 % in Steps 1 and 2 to 43.5 % in Step 9 [6]. None-
theless, the scale more accurately predicts central 
geographic atrophy (43.5 % in Step 9) than NVAMD 
(4.8  % in Step 9, but 21.1  % in the less severe Step 
8) [6]. A simplified severity scale in AREDS Report 
No. 18 used large drusen and pigmentary changes 
in a 0–4 scale and demonstrated, when both were 
present bilaterally, the 5-year incidence of advanced 
AMD in at least one eye was 47.3 % [7]. While a top 
score of 4 identified 67.8  % of 5-year progressors to 
advanced AMD, it identified only 36.5 % progressing 
to NVAMD [7].
Blue Mountains Eye Study investigators [8], using an 
AREDS simplified severity scale, found a generalized 
estimating equation model showed 61.5  % of patients 
with bilateral drusen ≥125 μm and bilateral retinal pig-
ment epithelial changes progressed to advanced AMD 
over 10  years. Assuming 70  % of those advanced AMD 
cases were neovascular [2], approximately 43  % of 
NVAMD cases would be identified. This converts to 
(57.0 % × 161,754 cases=) 92,200 new NVAMD patients 
aged ≥65 in the US not identified by phenotypic markers 
annually [1–3].
Multiple advances in AMD genetics have been made 
over the last decade [9-17]. A report by Seddon et al. [12], 
created models predicting advanced AMD development. 
They approach include age, gender, education, smok-
ing, body mass index, single nucleotide polymorphisms 
in the CFH, ARMS2/HTRA1, C3, C2, and CFB genes, as 
well as important markers discovered through two large 
genome-wide association studies [4, 13–16]. With the 
inclusion of cholesterol metabolic markers CETP, LIPC 
and ABCA1, the progression prediction to advanced 
disease within 10  years achieved unparalleled accu-
racy (C = 0.90) [4]. Using this model for a dichotomous 
risk score (“risk” vs “non risk”), Yu et al. [4], showed the 
5-year progression of Category 3 AMD cases to advanced 
AMD could be predicted with both sensitivity and speci-
ficity over 80  %; sensitivity over 10  years was ≥90  %. 
There was a 10-year 20  % progression to neovascular 
AMD (Table 1) using phenotypic and genotypic markers, 
but they identified 90 % of people progressing to neovas-
cular AMD [4].
Neovascular AMD therapy
Intravitreal ranibizumab therapy for NVAMD is among 
the greatest medical advances over the decade [18–24]. 
Earlier therapy has a better visual prognosis than later 
therapy [20]. Thus, it is hoped greater risk awareness will 
allow patients to seek earlier care.
Considering the importance of earlier ranibizumab ther-
apy, the authors undertook a Value-Based Medicine® (VBM) 
[22–24], societal, cost-utility analysis to assess the patient 
preference-based, comparative effectiveness and cost-effec-
tiveness (cost-utility) of genetic testing for NVAMD.
Methods
Features associated with genetic testing for NVAMD, and 
the economic modeling assumptions used are listed in 
Table  2. Comparative effectiveness quantified the incre-
mental patient value gain (improvement in quality-of-life 
and/or length-of-life), though length-of-life change was 
not included, since better vision has not been well shown 
to lengthen life. Outcomes were measured in: (1) per-
cent value gain, and (2) quality-adjusted life-year (QALY) 
gain [18, 20, 22–25]. QALY gain was calculated by mul-
tiplying: (utility gain) × (years of interventional benefit). 
Financial metrics include: (1) cost-utility ratio, $/QALY, 
or dollars expended per QALY gained, associated with 
genetic testing-enabled, early-treatment ranibizumab for 
NVAMD, and (2) societal costs.
AMD demographics
The AREDS Research Group [5–7] defined four cat-
egories of AMD and showed oral supplements decrease 
the progression of Category 3 AMD (macular drusen 
≥125  µm) to NVAMD, though not from Category 3 to 
central geographic atrophy. Yu and colleagues [4] refined 
the AREDS four-category model to a five-category model, 
separating AREDS [5–7] advanced AMD cases into cen-
tral geographic atrophy (Category 4) and NVAMD (Cat-
egory 5) in their genotypic/phenotypic study of AMD. 
Approximately 1.54 million people had NVAMD in the 
Table 1 Progression for  2560 AREDS AMD (Category 1–3 
at Baseline) patients over 10.3 years (Yu et al. [4])
Includes patients treated and not treated with AREDS supplements [5]
AREDS Age-Related Eye Disease Study, AMD age-related macular degeneration, 
NA not applicable
AMD category n Progressed to next stage No progression
1 713 494 (69 %) 219 (31 %)
2 1190 376 (32 %) 814 (68 %)
3 1527 578 (8 %) 949 (62 %)
3–4 280 280 (18 %) NA
3–5 298 298 (20 %) NA
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Table 2 Genetic testing for neovascular AMD. Cost-utility analysis model parameters and assumptions
Phenotypic Features
 Identification of 5-year progression to advanced AMD (age-related macular degeneration) using the AREDS (Age-Related Eye Disease Study) Simpli-
fied Scale for AMD [7] Identified 67.8 % of progressors to atrophic AMD, but only 36.5 % of those progressing to neovascular AMD
Genotypic Features (from Yu et al. [4])
SNPs in the following genes
Gene [4] Hazard ratio [4] for neovascular AMD p-value Notes
CFH—3 SNP 1.37 2.2 × 10−4 Higher risk
ARMS2/HTRA1—2 SNPs 1.27 5.3 × 10−3 Higher risk
C2 0.60 0.14 Uncertain status
C3 1.25 0.02 Higher risk
CFB 0.57* 0.02 Lower risk
LIPC 0.57* 0.04 Lower risk
CFI 0.87 0.10 Uncertain status
TIMP3 0.79 0.30 Uncertain status
CETP 1.17 0.06 Uncertain status
ABCA1 0.97 0.79 Uncertain status
COLSA1 1.2 0.21 Uncertain status
APOE—2 SNPs 0.97 0.85 Uncertain status
Genetic profiles
 High-risk = homozygous on all genetic loci for the alleles that increase the risk of advanced AMD
 Medium-risk = heterozygous on genetic loci for the alleles that increase/decrease the risk of advanced AMD
 Low-risk = homozygous on all genetic loci for alleles that decrease the risk of advanced AMD
 As per Yu et al. [4], all genes listed above are assumed to be tested for. This conservative assumption likely biases against the financial value gain and 
cost-effectiveness by increasing what will likely be decreased genetic costs in the future
Progression to neovascular AMD
 Incremental, 10-year progression rate to neovascular AMD for Category 3 AMD patients with: a past smoking history, BMI of 25–29, normal fellow eye 
and greater than a high school education [4]




 Among people with Category 3 AMD, 20 % will progress to neovascular AMD over 10 years [4]. (SNP = single nucleotide polymorphism, 
* = decreased chance of progression to neovascular AMD, BMI = basal metabolic index)
Neovascular AMD therapy
 Clinical features, MARINA study [18, 20, 23]
  All participants had minimally classic or occult, subfoveal choroidal neovascularization
  Baseline vision in the affected eye: 20/40–20/320
  Choroidal neovascular lesions <12 disc areas at baseline
  Mean baseline vision: 20/80-1 in the ranibizumab treatment and sham therapy cohorts
  Mean baseline age: 75 years
  Participants randomized 1:1:1 to: (1) 0.5 mg intravitreal ranibizumab dose (n = 240), (2) 0.3 mg intravitreal ranibizumab dose (n = 238) or (3) sham 
injection cohort (n = 238)
  The 0.5 mg ranibizumab dose was more effective than the 0.3 mg dose, and was thus the dose approved by the Food & Drug Administration and 
used in the current analysis [18]
  Treatment cohort (0.5 mg ranibizumab) mean vision: MARINA Study for years 1 and 2, then LOCF (last observation carried forward) of clinical trial 
data for years 3–12 [23]
  Eligible, MARINA sham cohort patients were treated with ranibizumab following the end of the randomized portion of the trial after 24 months. 
Thus, sham treatment, control cohort data utilized mean vision in the MARINA Study [18] for years 1 and 2, and a Lineweaver–Burke plot meta-
analysis control cohort from six randomized, neovascular AMD clinical trials for years 3–12 of sham therapy [25]
  Adverse event disutility QALYs, a total of 0.045 QALY, were used to calculate adverse event QALYs subtracted from total patient value gain
  The average participant received 22 × 0.05 cc intravitreal injections, given approximately monthly, over 2 years
  Mean life expectancy: 12 years for the control and ranibizumab study cohorts [49]
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Table 2 continued
Genetic profile 10-year progression Percent of progressors detected
Value-Based Medicine©, base case, cost-utility analysis parameters for the AMD genetic screening, cost-utility analysis [18, 20, 22, 23]
 The patient value and financial value gains are those associated with genetic screening for neovascular AMD making possible the incremental earlier 
detection and earlier ranibizumab therapy for neovascular AMD
 Model timeline: 12 years = mean life expectancy for average neovascular AMD patient [18]
 Baseline vision in the early-treatment, ranibizumab therapy cohort was 20/40–20/80. Final vision outcome was 20/40–1 [20]
 20/40-1 vision in each eye equates with a utility of 0.789 [30, 39]
 Baseline vision in the late-treatment, ranibizumab therapy cohort was 20/160-20/320. Final vision outcome was 20/160+2.[20]
 20/160+2 vision in each eye equates with a utility of 0.0.658 [29, 30]
 Loss of vision in a first eye results in a utility loss of 0.0398 [35]
 The incremental cost-utility analysis per patient utilizes the incremental patient and incremental financial value gains associated with early-treatment 
ranibizumab therapy (baseline treatment vision 20/40–20/80) for neovascular AMD versus late-treatment ranibizumab therapy (baseline treatment 
vision of 20/160–20/320) [20]
 The costs of genetic screening were compared with the patient value gains and cost savings conferred by early-treatment ranibizumab therapy (ver-
sus late-treatment ranibizumab therapy) made possible by genetic screening
 The direct ophthalmic medical treatment costs were the same in the early-treatment, ranibizumab therapy and late-treatment, ranibizumab therapy 
cohorts, and therefore were not considered incremental costs
 Only Category 3 AMD eyes in patients who were 65 years of age were tested with genetic screening
 Category 3 AMD cases (drusen >125 μm) annually in the United States in a 65-year-old cohort = 944,400 [1–3]
 22.5% of baseline Category 3 cases have a high-risk genetic profile to develop neovascular AMD [4]
 The phenotypic appearance of Category 3 AMD determines the use of AREDS supplement therapy to decrease the incidence of progression to neovas-
cular AMD [5]. Since the use of AREDS supplements in Categories 1 and 2 AMD has not yet been shown to reduce progression to neovascular AMD 
[5]. Genetic screening was not presumed to be of benefit to detect whether to use AREDS supplements at an earlier stage than Category 3 AMD
 Genetic testing of Category 4 AMD patients for the development of more severe atrophic changes was not presumed to be of benefit
 Genetic testing was not presumed to be of benefit if one eye was already affected by neovascular AMD or advanced atrophic AMD
 Patients underwent genetic screening at age 65, since only 5.6 % of neovascular AMD develops in patients under the age of 65 years [18]
 Baseline time: First presentation for neovascular AMD occurs at a mean age of 75 years, as per a combination of multiple clinical trials dealing with 
therapy for neovascular AMD [18–20, 23, 24, 50, 51]
 The outcomes included the QALY (quality-adjusted life-year) gain, percent patient value (quality-of-life) gain, and the CUR (cost-utility ratio), or dollars 
expended per QALY gained ($/QALY) [22]
 All eyes with neovascular AMD were presumed treated with ranibizumab, including cases presenting with bilateral disease
 Time tradeoff utilities were derived from a database of over 1100 ophthalmic patients with respective levels of vision loss [22–24, 30–38]
 Cost perspectives: societal and 3rd party insurer
 The societal cost perspective included those saved by the better mean vision outcome associated with early-treatment ranibizumab therapy versus 
late-treatment ranibizumab therapy. They include: (1) direct ophthalmic medical costs = AMD genetic testing costs + incremental annual ophthalmic 
examination and annual optical coherence tomography costs, (2) direct non-ophthalmic medical costs saved = decreased depression costs, decreased 
trauma costs, decreased Skilled Nursing Facility costs, decreased nursing costs and other, as yet unidentified, medical costs [40]. (3) direct non-medical 
costs (caregiver) saved [41] and (4) indirect medical (employment) costs saved [3, 42]
 The 3rd party insurer cost perspective includes: (1) direct ophthalmic medical costs expended and (2) direct non-ophthalmic medical costs saved
 Cost basis: 2012, average, national, Medicare Fee Schedul
 Net present value (NPV) analysis discounted patient value outcomes and costs at a 3 % annual rate. All costs were converted to 2012 US real dollars [22]
 A combined-eye model, a weighted average of first-eye and second-eye models, was utilized to calculate QALY gain per early-treatment case over 
late-treatment case [23, 24]
 Taking into account the annual conversion rate, the QALY gain and financial value gain accrual rate of 1st eyes with NVAMD was 85.3 % that of 2nd eyes
 Second eyes in the per patient, early treatment benefit from ranibizumab were assumed to have the same visual outcome as treated first eyes
 For the overall Category 3 cohort undergoing genetic testing, the early-treatment ranibizumab QALY gain and costs per person were multiplied by: 
(Percent of first eyes with presenting vision ≤20/160, or 78.0 %) × (Percent of second eyes with presenting vision ≤20/160 = 62.2 %) × (Sensitivity 
of genetic testing with phenotypic features for detecting 10-year conversion to NVAMD = 90 %). Thus, overall Category 3 cohort results average 
(78.0 % × 62.2 % × 90 % =) 43.7 % × (per patient value and financial value outcomes)
 Conversion rates of second eyes to neovaoscular AMD with Markov modeling demonstrated the patient value (QALY gain)
 It was assumed that the majority of patients converted to neovascular in one eye first and thus treated with ranibizumab initially in this first eye, 
though a small number of cases might have present with bilateral neovascular AMD. This assumption is conservative and biases against the analysis 
by decreasing the overall patient and financial gains
AMD age-related macular degeneration, NVAMD neovascular age related macular degeneration, QALY quality-adjusted life-year, CUR cost-utility ratio, MARINA 
Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-Related Macular Degeneration, SNP single nucleotide 
polymorphism
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US in 2012 [2, 3]. Central geographic atrophy (AREDS 
Category 4) in at least one eye was present in 1.24 mil-
lion, and 8.34 million had drusen ≥125 µm (AREDS Cat-
egory 3). The 944,000 people aged 65 years with Category 
3 drusen (≥125 µm) annually were those who were theo-
retically screened in our cost-utility model [2, 3].
Fifteen-year, incidence data from the Beaver Dam 
Study [26] suggest approximately 171,350 new cases of 
NVAMD develop annually in the US. Among these, 5.6 % 
in the Minimally classic/occult trial of the Anti-VEGF 
antibody Ranibizumab In the treatment of Neovascular 
AMD (MARINA) Study [18, 20] presented before age 65. 
We excluded that percentage from our analysis since our 
model assumed genetic testing at age 65, leaving 161,754 
annual new cases.
Yu et  al. [4], noted 20  % of Category 3 patients pro-
gressed to NVAMD (Category 5 AMD) over 10  years 
(Table 1). They also found 22.5 % (343/1527) of Category 
3 patients had a high-risk genetic profile (homozygous 
for genetic loci on relevant alleles). Among progressors 
to NVAMD, 90  % had a high-risk genetic profile [4]. 
Thus, genetic testing for Category 3 AMD patients iden-
tified 90 % of progressors to NVAMD, 47 % higher than 
the 43.0 % identified over 10 years in the Blue Mountains 
Study [8].
Utility analysis
The quality-of-life associated with AMD has been quan-
tified using time tradeoff utility analysis [27–37]. Utility 
anchors are 1.00 (normal bilateral vision permanently) 
and 0.00 (death). Vision utilities correlate most highly 
with acuity in the better-seeing eye, rather than the 
underlying disease [28]. As vision in the better-seeing eye 
decreases, the associated utility decreases [27–35]. Vision 
of no light perception bilaterally has an associated utility 
of 0.26 [30].
Ophthalmic utilities are valid [32], reliable [33], and 
negligibly affected by systemic comorbidities [34]. The 
Wills Eye Institute Institutional Review Board approved 
utility acquisition.
Ophthalmologists underestimated the quality-of-life 
associated AMD levels by 96–750 % compared to AMD 
patients, with community utility estimates even more dis-
parate [31]. Thus, VBM cost-utility analyses use patient 
utilities [22]. Utilities herein were derived from a >1100 
direct interview, vision utility database from the Center 
for Value-Based Medicine® [28–37].
Value-Based Medicine®
Value-Based Medicine® (VBM) integrates the highest 
level, evidence-based, clinical trial data with standardized 
inputs, including: (1) time tradeoff utilities, (2) patient 
utility respondents, (3) a national Medicare Fee Schedule, 
and (4) societal and 3rd party insurer cost perspectives 
[22–24]. VBM has been used extensively in ophthalmol-
ogy, especially for AMD interventions [22–24, 36, 37].
Originated at the Center for Value-Based Medicine® 
and based upon primary, ophthalmic patient data, the 
first-eye model assumes vision loss occurs in one eye, 
while the fellow eye has good vision [22–24, 36]. In this 
instance, full patient value gain is not accrued until the 
fellow eye also develops NVAMD. Utility data from 
Center for Value-Based Medicine files demonstrate a 
mean utility difference of 0.0398 between unilateral good 
vision and 20/40–20/80 vision in the second eye, versus 
unilateral good vision and ≤20/160 vision in the second 
eye. This utility gain was weighted to appropriate first-eye 
model instances herein.
The second-eye model assumes first-eye vision has 
been lost and the second eye is affected [22–24, 36]. 
Thus, greater patient value gain occurs with ranibizumab 
therapy. The combined-eye model used here integrates 
weighted first-eye model and second-eye models [22, 24]. 
Extrapolation of data from Barbazetto and colleagues 
[39] with Markov modeling (TreeAgePro for Healthcare 
2012, Williamstown, MA, USA) showed 82 % of patients 
with unilateral NVAMD in the MARINA/ANCHOR tri-
als developed bilateral NVAMD within 5 years, rising to 
96 % by 12 years, the model timeline (Table 3).
Patient value gain
Shah and DelPriore [25] modeled the natural course 
of untreated NVAMD using control cohorts from six 
randomized, NVAMD trials. In a meta-analysis using 
Lineweaver–Burke plots, they demonstrated mean vision 
loss to 20/640 over 8–9  years, after which vision stabi-
lized. Increasing time since NVAMD highly correlated 
with increasing vision loss.
A double-blind, randomized, clinical trial, MARINA 
participants had 20/80 baseline vision in both ranibi-
zumab-treatment and sham-treatment cohorts. The 
24-month, mean, ranibizumab-treatment cohort vision 
was 20/63, while mean sham-treatment vision was 
20/160−2 [18, 20].
Shah and DelPriore data [25] were employed to model 
MARINA 25–144 month, non-randomized sham results 
since many sham-treatment patients were allocated to 
ranibizumab therapy after month 24. Treatment cohort 
data for months 25–144 were modeled in a LOCF (last 
observation carried forward) fashion. Twelve years was 
selected as the model length since this was the average 
life expectancy of the average NVAMD patient.
An analysis of baseline vision in 50 consecutive Penn-
sylvania/New Jersey/Delaware patients presenting with 
first-eye NVAMD in the vitreoretinal practice of author 
GCB since 2010 was undertaken. The mean, baseline, 
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first-eye vision was 20/182, while that in the fellow eye 
was 20/47. Overall, 78  % (39/50) presented with vision 
≤20/200 in the first eye. Only 18  % (9/50) had first-eye 
vision ≥20/80 vision at presentation (Table 4).
An analysis of 98 consecutive patients presenting with 
second-eye NVAMD revealed a mean vision of 20/94. 
Overall, 62.2  % had vision ≤20/160. The vision was 
≥20/80 in 37 % of eyes (Table 4).
Critical to our analysis, the excellent report by Boyer 
et  al. [20] demonstrated NVAMD early-treatment eyes 
(baseline vision 20/40-20/80) had better long-term vision 
(mean 20/40−1) than late-treatment eyes (baseline vision 
≤20/160 and mean long-term vision of 20/160+2) [20]. 
Total patient value gains (Table 4), to account for those 
eyes presenting with ≤20/160 vision and other parame-
ters, had an overall multiplier of 78 % (1st eyes presenting 
with vision ≤20/160) × 62.2 % (2nd eyes presenting with 
≤20/160) × 85.7 % (combined-eye multiplier to account 
for NVAMD conversion to both eyes)  ×  90  % (genetic 
testing sensitivity)  =  37.4  %. Adverse events disutilities 
were subtracted in early-treatment and late-treatment 
cohorts for months 1–144 [23].
Costs
The mean, incremental, 12-year, direct, ophthalmic medi-
cal costs included genetic testing/monitoring. Ranibizumab 
therapy costs were excluded since they were assumed simi-
lar for early-treatment and late-treatment cohorts, though 
differences were analyzed in the sensitivity analysis.
Based upon work by Yu et al. [4], genetic testing costs 
are shown in Table  5. Compounded from $1461 at the 
time of genetic testing (age 65) to base-case age 75 at the 
initiation of ranibizumab therapy, they totaled $1906. A 
$299 cost for an extra, annual, ophthalmic examination 
and optical coherence tomogram (three/year rather than 
two/year) was included in the genetic costs for the 22.5 % 
[4] of genetic-screened high-risk patients progressing to 
NVAMD. The total cost for genetic testing/monitoring of 
Stage 3 AMD patients was $2205 per capita.
The base-case scenario shows that 30.3 Category 3 
AMD patients required screening/monitoring to facili-
tate one early-treatment. The total cost of screening/
monitoring for each early-treatment patient was there-
fore $66,873 (30.3 × $2205).
Twelve-year negative costs accrued against genetic test-
ing/monitoring costs [4, 20, 39–41]. Costs saved by early-
treatment, vs. late-treatment (Table  6), are addressed 
below [39–41].
Javitt and colleagues [39] demonstrated increased 
direct, non-ophthalmic, medical costs for depression, 
trauma, Skilled Nursing Facilities, nursing homes and 
unidentified entities associated with vision loss (Table 6). 
Table 3 Fellow eye conversion to neovascular AMD in the 
MARINA/ANCHOR trials, Barbazetto et al. [39]
Baseline, year 1 and year 2 prevalences are based upon primary data [39], while 
years 3–12 are based upon the average incidence of conversion to neovascular 
during years 1 and 2, using a last observation carried forward (LOCF) 
methodology with Markov modeling
AMD age-related macular degeneration




Cumulative, incremental,  
conversion rate of the 53.6 % 





Year 1 21.2 57.7
Year 2 38.0 66.8
Year 3 49.8 73.1
Year 4 59.5 78.3
Year 5 67.2 82.4
Year 6 73.4 85.7
Year 7 78.5 88.5
Year 8 82.6 90.6
Year 9 85.9 92.4
Year 10 88.6 93.9
Year 11 90.7 95.0
Year 12 92.5 96.0
Final 92.5 96.0
Table 4 Category 3 AMD cases undergoing genetic testing: baseline vision in neovascular AMD eyes in clinical practice 
integrated with MARINA trial presenting percentages
AMD age-related macular degeneration, NA not applicable
a MARINA (Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular AMD) clinical trial [18, 20]
Model n % of baseline  
patients [18, 20]a
Mean vision % with initial  
vision 20/40–20/80
% with initial  
vision ≤20/160
A. 1st eye 50 53.6 20/182 18 78.0
B. 2nd eye 98 46.4 20/84 37 62.2
Both eyes (A × B) 148 100.0 20/136 6.7 48.5
C. Sensitivity of genetic testing 148 90 NA A × B × C = 6.0 % A × B × C = 43.7 %
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This 12-year cost gained by improving vision per early-
treatment patient is (−$40,914) (Table 6).
Schmier and associates [40] reported increasing car-
egiver costs associated with decreasing levels of vision. 
Early-treatment ranibizumab therapy resulted in a 
12-year, (−$172,443) caregiver cost saving vs. late-treat-
ment therapy (Table 6).
Vision loss decreases employment by 45.6  % and 
hourly wage loss by 32.5 % referent to age-matched nor-
mals, resulting in 36.7  % of normal earnings (Table  6) 
[41]. Integrating age-related, US employment levels, 
early-treatment ranibizumab therapy accrued a 12-year 
employment cost gain of (−$14,098) [41].
Results
Patient value gain
The mean MARINA, early-treatment, 20/40−1 vision out-
come correlated with a 0.789 utility, while late-treatment 
20/160+2 vision correlated with a 0.658 utility (Table  7) 
[20, 29, 30]. Additionally, 17.9  % of early-treatment, 
MARINA eyes achieved vision ≥20/25 bilaterally [20], 
(utility = 0.97 for bilateral 20/20–20/25 and 0.89 for uni-
lateral 20/20–20/25). This conferred a 12-year, additional 
0.121 QALY gain for early-treatment, a 2.0 % quality-of-
life gain. First-eye therapy conferred 0.0884 QALY gain, a 
1.5 % quality-of-life gain.
The 12-year, combined-eye model, QALY accrual 
for each case of screening-facilitated, early-treatment, 
ranibizumab therapy was 0.845 QALY, a mean, a 14.1 % 
quality-of-life gain over sham therapy. Late-treatment 
accrued 0.250 QALY, a 4.2  % quality-of-life gain over 
sham-therapy. Thus, early-treatment conferred a, 10.0 %, 
absolute, quality-of-life gain, a 0.595 QALY gain per 
early-treatment patient. The QALY gain per genetic 
screened/monitored patient was 0.0177, a 0.33 % quality-
of-life gain. Bilateral good vision QALY gain and first-eye 
model QALY gain were weighted appropriately
Costs
Direct ophthalmic medical costs for early-treatment 
vs. late-treatment ranibizumab therapy were assumed 
the same, thus excluded in the base case analysis, but 
addressed in the sensitivity analysis.
Assuming one early-treatment case per 30.3 genetically 
screened cases, the base-case genetic testing/monitoring 
cost for each early-treatment case was $66,873 (Table 6).
The incremental negative cost for each early-treatment 
ranibizumab patient was (−$227,455) (Table  6). With 
genetic testing/monitoring costs for Category 3 patients 
screened of $66,873 for each incremental early-treatment 
case, the overall societal cost per early-treatment case 
was (−$160,582) (Table 6).
The national, direct ophthalmic cost for genetic test-
ing/monitoring for an annual cohort of 944,400 Cat-
egory 3 AMD patients million was $2.082 billion. Total 
negative costs were $7.083 billion. This resulted in a 
12-year, financial return-on-investment (ROI) of 240  % 
referent to genetic testing/monitoring costs. An incre-
mental $260 million societal saving occurred for each 
1 % of patients undergoing early-treatment ranibizumab 
therapy. When genetic testing facilitated an incremental 
12,965 (8.0 %) of the 161,754, annual NVAMD patients 
in the US to undergo early-treatment ranibizumab ther-
apy, an overall, net financial gain for society accrues 
Table 5 Genetic testing costs for genes as per Yu et al. [4]
CPT Current Procedural Terminology, published by the American Medical Association, NLA National Limitation Amount, all cost in 2012 US nominal dollars
CPT code Explanation Multiplier NLA Total NLA
83891 DNA Isolation 1 $5.7 $5.7
83900 Amplification of patient nucleic acid, multiplex, first two nucleic sequences 1 $47.8 $47.8
83901 Amplification of patient nucleic acid, multiplex, each additional acid sequence 10 $23.7 $237
83892 Digestion of amplified DNA with restriction endonuclease enzyme, each 2 $5.7 $11.4
83914 Mutation identification by enzymatic ligation or primer extension, single segment, each 
segment [e.g. oligonucleotide ligation assay (OLA), single base chain extension (SBCE), 
or allele-specific primer extension (ASPE)]
15 $23.7 $356
83912 Interpretation and report 1 $5.7 $5.7
83896 Nucleic acid probe, each 15 $5.7 $85
83903 Molecular diagnostics; mutation scanning by physical properties, single segment, each 15 $23.7 $356
83908 Molecular diagnostics; signal amplification of patient nucleic acid, each nucleic acid 
sequence
15 $23.7 $356
Cost per patient tested $1461
Adjusted for a genetic testing age of 65 years and ranibizumab. Total treatment age of 75 years (compounded at 3 % annually) $1906
Including the $299 incremental yearly ophthalmic examination and optical coherence. Total tomogram in the 20 % of patients with a high-
risk genetic score [4]
$2205































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 10 of 16Brown et al. Int J Retin Vitr  (2015) 1:19 
at the rate of $160,582 per additional early-treatment 
patient.
The financial ROI distribution, assuming that genetic 
testing for 30.3 Category 3 AMD cases resulted in 
one incremental early-treatment case is shown in 
Table  8. The negative cost for each patient screened 
(cost of $2205) was (−$7500), an overall societal cost 
of (−$5295), also a 240  %, 12-year societal ROI. The 
ROI offset Medicare screening costs by 35 %, Medicaid 
costs by 63 % and commercial insurer costs by 22–24 %. 
Patients had the greatest ROI for out-of-pocket genetic 
testing costs, a net $6725. This converted to a 12-year 
16,945 % ROI.
Cost-utility ratio (CUR)
$144,000/QALY For a $144,000/QALY CUR, the 
upper limit of cost-effectiveness in the US accord-
ing to World Health Organization criteria [43], an 
incremental 4.1  % of annual NVAMD patients were 
required to undergo genetic testing-enabled, early-
treatment, ranibizumab therapy. This 4.1 % converts to 
6634 patients among the 161,754 annual cohort of new 
NVAMD patients, 92,200 of whom are not identified 
as high risk to develop NVAMD by phenotypic fea-
tures alone (Table 9) [1–3, 9]. It also equates to 1 per 
142 of the 944,000 Category 3 AMD patients screened 
at age 65 annually. For a 3rd party insurer CUR of 
$144,000/QALY, an increment of 10.1  % of all annual 
NVAMD patients had to undergo early-treatment for 
cost-effectiveness (Table 10).
For a $100,000/QALY CUR, the upper limit of cost-
effectiveness commonly utilized in the US [22], an incre-
mental 4.5 % of annual NVAMD patients were required 
to undergo early-treatment, ranibizumab therapy for 
cost-effectiveness (Table 9). For a 3rd party insurer CUR 
of $100,000/QALY, an incremental 13.2  % of all annual 
NVAMD patients had to undergo early-treatment for 
cost-effectiveness (Table 10).
Sensitivity analysis
Sensitivity analysis (Table  11) showed decreasing age 
made genetic testing considerably less cost-effective (age 
40 societal CUR  =  $1,088,253/QALY) and 3rd party 
insurer CUR = $231,137/QALY). Deleting extra ophthal-
mic monitoring costs had negligible effect, while decreas-
ing genetic testing price improved cost-effectiveness. If 
the cost of ranibizumab therapy for early-treatment cases 
is twice that of the ranibizumab cost for late-treatment 
cases, an increment of approximately 6.0  % (9700) of 
NVAMD cases undergoing early-treatment ranibizumab 
therapy is required for genetic testing to be cost-effective 
using WHO criteria.
Discussion
Our analysis demonstrated, using MARINA Trial data 
[20], that each incremental, early-treatment, ranibizumab 
case of NVAMD conferred a combined-eye model, 
14.1 % quality-of-life improvement, versus a 4.2 % qual-
ity-of-life improvement with late-treatment (baseline 
vision of 20/160–20/320) (Table 7), a 10.0 %, incremen-
tal, patient value gain. The net, societal, financial ROI was 
$160,582 per early-treatment case, a net $5295 ROI per 
patient screened.
While the US has no formal, cost-effectiveness upper 
limits, interventions costing ≤$100,000/QALY are gen-
erally believed cost-effective [22]. Formal World Health 
Organization standards indicate interventions costing 
≤3× GDP per capita (~US $144,000) per DALY (disabil-
ity-adjusted life-year), a metric similar to the QALY, are 
cost-effective (Tables  9, 10) [42]. Screening is still cost-
effective if only 4.1 % overall NVAMD cases, or 7.2 % of 
cases not forecast phenotypically, receive genetic testing-
facilitated early-treatment ranibizumab therapy
The presence of AMD, even with good vision, can 
decrease a patient’s quality-of-life [31]. We believe low-risk/
medium-risk genetic profiles for progression to advanced 
AMD, likely allay patient fears and improve patient quality-
of-life. We are uncertain how a positive, high-risk genetic 
profile affects patient quality-of-life, but since only 22.5  % 
of screened patients have a high-risk profile [4], the overall 
quality-of-life gain in the low-risk and medium-risk genetic 
profile cohorts could possibly outweigh total quality-of-life 
loss in the high-risk profile cohort.
Wealth of the nation
The data herein support the work of Nordhaus [43], the 
Yale economist who estimated 50  % of the wealth of 
the United States created during the twentieth century 
occurred from healthcare advances. While secondary to 
patient value gain, the increase in national wealth asso-
ciated with medical interventions is an important factor. 
If 12,965 (8.0 %) of the 62,279 NVAMD cohort patients 
not predicted phenotypically to develop NVAMD are 
recruited to early-treatment due to genetic testing, 
the cost of testing is at a breakeven point. Each patient 
undergoing early-treatment in addition adds $160,582 to 
societal wealth.
When to genetically screen
We selected the age of 65 years as the most cost-effective 
age for genetic screening since it encompasses 94.4 % of 
those who develop NVAMD [18]. As sensitivity analy-
sis shows, the earlier genetic testing is performed, the 
greater the expense of testing, since analyses must 
account for the time value of money.
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Patients with NVAMD may not come in promptly 
due to numerous reasons, including: (1) unawareness 
of NVAMD symptoms [44], (2) not realizing vision is 
decreased in one eye, (3) denial, (4) absence of pain, 
(5) believing refraction or cataract is their problem, (6) 
cognitive difficulties and (7) others. In non-ophthalmic 
specialties, well-defined follow-up plans [45], good rela-
tionships with healthcare providers [46], and focused 
programs [46] result in greater patient adherence. While 
we cannot be certain, we are hopeful that high-risk phe-
notypic/genotypic profile patients will be especially 
aware to present promptly when they develop NVAMD 
symptoms.
To our knowledge, convincing data that show more 
frequent ophthalmic screening allows earlier NVAMD 
treatment are lacking. Nonetheless, we included the extra 
costs of screening herein to be conservative in our eco-
nomic analysis.
Some might argue genetic testing of Category 3 AMD 
cases is of no benefit over phenotypic progression 
parameters. While the case for Category 4 atrophic AMD 
centrally or unilateral NVAMD, phenotypic progression 
parameters for Category 3 AMD are less reliable [6, 47]. 
Furthermore, only a small increment (4.1  %) in genetic 
testing-enabled, early-treatment, ranibizumab therapy 
cases is necessary for screening cost-effectiveness. As 
genetic testing likely increases in accuracy and decreases 
in price, the patient and financial value gains will be more 
pronounced. Though the study was performed in US dol-
lars, WHO criteria are very similar for many developed 
countries globally [48].
Conclusions
In summary, genetic screening for NVAMD is cost-
effective by the WHO standard of $144,000/QALY if it 
facilitates early-treatment with ranibizumab for an incre-
mental 4.1 % of annual NVAMD cases. If genetic testing 
allows earlier ranibizumab therapy for an incremental 
one NVAMD case per 142 Category 3 AMD patients 
screened, it remains cost-effective by WHO standards. 
Using the often accepted US upper limit of cost-effec-
tiveness of $100,000/QALY, genetic testing for NVAMD 
is cost-effective if it facilitates an incremental 4.5  % of 
annual NVAMD cases to undergo early-treatment ranibi-
zumab therapy. This information can be used by clini-
cians to decide whether genetic testing for neovascular 
age-related macular degeneration is appropriate for their 
patients.
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